Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.

BMC medical genomics - 10 Nov 2020

Lee Eunjin, Lee Ji Won, Lee Boram, Park Kyunghee, Shim Joonho, Yoo Keon Hee, Koo Hong Hoe, Sung Ki Woong, Park Woong-Yang

Abstract excerpt

BACKGROUND: MYCN amplification is the most important genomic feature in neuroblastoma (NB). However, limited studies have been conducted on the MYCN non-amplified NB including low- and intermediate-risk NB. Here, the genomic characteristics of MYCN non-amplified NB were studied to allow for the identification of biomarkers for molecular stratification. METHODS: Fifty-eight whole exome sequencing (WES) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Exome Sequencing
Share to Gene Amplification

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunotherapy

Share to N-Myc Proto-Oncogene Protein

Share to Neoplasm Metastasis

Share to Neuroblastoma

Share to Oncogene Proteins, Fusion

Share to Sequence Homology, Nucleic Acid

Source

Open in PubMed Open full text

Identifiers

PMID: 33172452
DOI: 10.1186/s12920-020-00819-5
PMCID: PMC7653769

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.PMID 33172452Read ↗

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastomaSemantic proximity Read ↗

Whole exome sequencing of high-risk neuroblastoma identifies novel non-synonymous variants.Semantic proximity Read ↗

Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN -Not-Amplified Human NeuroblastomaSemantic proximity Read ↗

The genetic landscape of high-risk neuroblastoma.Semantic proximity Read ↗

Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.Semantic proximity Read ↗

Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression.Semantic proximity Read ↗

Molecular targeting therapies for neuroblastoma: Progress and challengesSemantic proximity Read ↗

High-risk, Expression-Based Prognostic Long Noncoding RNA Signature in NeuroblastomaSemantic proximity Read ↗

Genetic discoveries and treatment advances in neuroblastoma.Semantic proximity Read ↗

Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patientsSemantic proximity Read ↗

Tumor Microenvironment in Neuroblastoma and Immunotherapeutic Approaches: Towards More Effective TreatmentSemantic proximity Read ↗

The Neuroblastoma Microenvironment, Heterogeneity and Immunotherapeutic ApproachesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.